Internal Medicine, Endocrinology, Diabetes, & Metabolism · Rapid City, SD
NPI
1063510691
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
640 Flormann St
Rapid City, SD, 57701
Phone (605) 755-3300
Groups this clinician bills Medicare through
Medicare paid, 2024
$138K
2,903 services
Medicare patients, 2024
850
Average age 70
Drug cost, 2024
$5.9M
8,168 prescriptions
Company payments, 2025
$3,757
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John Palmer was code 99232 (hospital e&m - subsequent), 929 times for 191 patients. In total John Palmer billed 2,903 services in 15 codes, and Medicare paid $138K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-10-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 929 | 191 | $56.92 | $53K |
| 99214 Office E&M - Established | Office | 517 | 379 | $62.56 | $32K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 515 | 383 | $11.67 | $6,009 |
| 99231 Hospital E&M - Subsequent | Facility | 253 | 86 | $35.16 | $8,896 |
| 99222 Hospital E&M - Initial | Facility | 164 | 150 | $89.14 | $15K |
| 99213 Office E&M - Established | Office | 135 | 125 | $41.80 | $5,643 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 114 | 85 | $11.54 | $1,315 |
| 99214 Office E&M - Established | Facility | 96 | 69 | $65.97 | $6,333 |
| 99204 Office E&M - New | Office | 59 | 59 | $87.32 | $5,152 |
| 99213 Office E&M - Established | Facility | 39 | 34 | $40.44 | $1,577 |
| 99203 Office E&M - New | Office | 23 | 23 | $52.55 | $1,209 |
| 83036 Blood Count | Office | 22 | 17 | $9.52 | $209 |
By year: 2022 $108K for 2,182 services; 2023 $111K for 1,985 services; 2024 $138K for 2,903 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 22 | 17 | $9.52 | $209 |
Medicare prescription drug claims, 2024
In 2024, the drug John Palmer prescribed most often to Medicare patients was Levothyroxine Sodium, with 931 prescriptions and refills. In total John Palmer wrote 8,168 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 931 | 2,195 | 242 | $8,535 |
| Ozempic Semaglutide | 605 | 898 | 114 | $810K |
| Jardiance Empagliflozin | 392 | 807 | 97 | $451K |
| Metformin Hcl Generic | 299 | 708 | 76 | $2,311 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 297 | 658 | 109 | $49K |
| Synthroid Levothyroxine Sodium | 291 | 504 | 59 | $18K |
| Metformin Hcl Er Metformin Hcl | 284 | 747 | 83 | $3,148 |
| Mounjaro Tirzepatide | 264 | 353 | 56 | $378K |
| Novolog Flexpen Insulin Aspart | 249 | 482 | 97 | $75K |
| Tresiba Flextouch U-100 Insulin Degludec | 236 | 498 | 68 | $141K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 165 | 382 | 41 | $238K |
| Pioglitazone Hcl Generic | 156 | 401 | 45 | $2,009 |
| Methimazole Generic | 150 | 265 | 35 | $1,764 |
| Atorvastatin Calcium Generic | 141 | 392 | 43 | $1,074 |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 137 | 265 | 29 | $100K |
Brand drugs: 4,461 claims; generic drugs: 3,134 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John Palmer $3,757 ($3,757 in general payments such as food, travel and fees) from 11 companies. The largest payer was Dexcom, Inc. with $2,683.
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. DXCM | 3 | $2,683 |
| Medtronic, Inc. MDT | 13 | $549 |
| Lilly USA, LLC LLY | 9 | $151 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $143 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $67.59 |
| Amgen Inc. AMGN | 2 | $42.75 |
| Ascendis Pharma Endocrinology Inc ASND | 2 | $42.31 |
| Pfizer Inc. PFE | 2 | $31.84 |
| Abbott Laboratories ABT | 1 | $16.02 |
| Novo Nordisk Inc NVO | 1 | $15.16 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.